The second phase clinical trials of Jinyukang in the treatment of mild to moderate depressive disorders

Objective To determine the efficacy and safety of Jinyukang for the patients with mild to moderate depressive disorders.Methods A total of 30 patients were treated with Jinyukang(600mg/d)and 29 patients were treated with fluoxetine (20mg/d)for 6 weeks. The efficacy were assessed by Hamilton Depression Rating Scale(HAMD), Hamilton Anxiety Scale(HAMA), Clinical Global Impression (CGI) and the safety was assessed by Adverse Event Scale.Results After six weeks treatment, the improvement rates of Jinyukang group and fluoxetine group were 73.33% and 75.86%,there was no difference between two groups (P0.05). The scores of HAMD and HAMA in two groups significantly decreased after treatment (P0.001).The main adverse events of two groups were nausea, dry mouth, insomnia , et al. There was no significant difference in incidence of adverse events between Jinyukang group and fluoxetine group.Conclusion Jinyukang is an effective antidepressant with less side effects and better safety.